Natural killer cell-dendritic cell crosstalk in the initiation of immune responses

Expert Opin Biol Ther. 2005 Sep:5 Suppl 1:S49-59. doi: 10.1517/14712598.5.1.s49.

Abstract

Dendritic cells (DCs) and natural killer (NK) cells play a critical role in early defences against cancer and infections. They specialise in complementary functions, including IL-12 or IFN-alpha/beta secretion and antigen presentation for the former, and IFN-gamma secretion and killing of infected or tumour cells for the latter. Both DCs and NK cells are also sensors of the immune system that have developed different, but partially overlapping, systems to identify pathology associated danger signals. Evidence of NK-DC interaction has accumulated recently. This interaction may lead to NK cell activation, DC activation, or apoptosis depending on the activation status of both cell types. Thus, the outcome of NK-DC crosstalk is likely to influence both innate and adaptive immune responses. This review addresses the molecular mechanisms under-lying the different NK-DC interactions, and their in vivo significance in anti-tumour or antimicrobial immunity. Finally, we discuss the potential clinical implications of this new field.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Cell Communication / immunology*
  • Clinical Trials as Topic
  • Cytokines / metabolism
  • Dendritic Cells / drug effects
  • Dendritic Cells / enzymology
  • Dendritic Cells / immunology*
  • Drug Evaluation, Preclinical
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / enzymology
  • Gastrointestinal Stromal Tumors / immunology
  • Herpesviridae Infections / immunology
  • Humans
  • Imatinib Mesylate
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / enzymology
  • Killer Cells, Natural / immunology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Membrane Proteins
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-kit / drug effects
  • Proto-Oncogene Proteins c-kit / metabolism
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Receptors, Immunologic / metabolism
  • Signal Transduction / immunology

Substances

  • Adaptor Proteins, Signal Transducing
  • Antineoplastic Agents
  • Benzamides
  • Cytokines
  • Membrane Proteins
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptors, Immunologic
  • TYROBP protein, human
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit